GLP-1 Market
LLY $1143.12 ▲ +0.0% NVO $37.54 ▲ +0.6% PFE $27.41 ▼ -1.4% VKTX $29.28 ▼ -2.2% KLRA $10.84 ▲ +4.3% GPCR $27.59 ▼ -0.3% RHHBY $52.51 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pegozafermin

Company
89bio, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 6, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pegozafermin and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06318169

    A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

    Not yet reported 89bio, Inc. 1350 participants Est. completion 2029-02 370 sites Stand-alone
    MASHMASLD
    View official trial listing →
  • Recruiting NCT NCT06419374

    A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

    Not yet reported 89bio, Inc. 762 participants Est. completion 2031-08 330 sites Stand-alone
    MASH
    View official trial listing →
  • Completed NCT NCT04048135

    A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

    Not yet reported, Not yet reported 89bio, Inc. 101 participants Est. completion 2022-01-19 26 sites Stand-alone
    MASH
    View official trial listing →
  • Completed NCT NCT04541186

    Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

    Not yet reported 89bio, Inc. 86 participants Est. completion 2022-05-31 48 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia
    View official trial listing →
  • Completed NCT NCT04929483

    Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

    Not yet reported 89bio, Inc. 222 participants Est. completion 2024-10-08 89 sites Stand-alone
    MASH
    View official trial listing →
  • Completed NCT NCT05022693

    PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

    Not yet reported 89bio, Inc. 8 participants Est. completion 2021-12-21 1 site Stand-alone
    MASH
    View official trial listing →
  • Completed NCT NCT05852431

    To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

    Not yet reported 89bio, Inc. 369 participants Est. completion 2026-04-09 177 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia
    View official trial listing →
  • Not yet recruiting NCT NCT07835243

    A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in Healthy Participants

    Not yet reported Hoffmann-La Roche 105 participants Est. completion 2027-03-02 Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Pegozafermin, BIO89-100

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.